Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074191 · ClinicalTrials.gov registry record · Phase 2
Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma
A Phase 2 study of Lymphoma, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT00074191: Completed Phase 2 study of Lymphoma, sponsored by OHSU Knight Cancer Institute.
NCT00074191 is a Phase 2 study of Lymphoma that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 1 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00074191, a Phase 2 study of Lymphoma, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy, such as methotrexate, procarbazine, lomustine, dexamethasone, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have primary CNS lymphoma.
Conditions Studied
Interventions
- DRUG dexamethasone
- DRUG methotrexate
- DRUG cytarabine
- DRUG lomustine
- DRUG procarbazine hydrochloride
Study Locations (1)
Oregon
- Oregon Health & Science University Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2000-01 |
| Est. Completion | 2000-10 |
| Phase | Phase 2 |
What the finished NCT00074191 record still lists
NCT00074191 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which dexamethasone is the first listed.
NCT00074191 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT00074191 about?
NCT00074191 is a clinical study titled "Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma". RATIONALE: Drugs used in chemotherapy, such as methotrexate, procarbazine, lomustine, dexamethasone, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effec...
What is the current status of trial NCT00074191?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2000-01. Estimated completion is 2000-10.
What conditions does trial NCT00074191 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00074191?
The interventions under investigation include: dexamethasone (DRUG), methotrexate (DRUG), cytarabine (DRUG), lomustine (DRUG), procarbazine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00074191?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00074191 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00074191's enrollment target sits among peer trials
1 299th of 299 the lowest of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia